Keyphrases
Diffuse Intrinsic Pontine Glioma
100%
89Zr-bevacizumab
17%
Pons
17%
Pediatric Glioma
17%
International Survey
17%
Glioma Patients
16%
Bevacizumab
15%
Tumor
14%
Healthcare Professionals
12%
Pediatric
12%
Disease Progression
12%
Working Diagnosis
11%
Tumor Classification
10%
Netherlands
10%
Erlotinib
10%
Clinical Trials
10%
Drug Delivery
9%
Drug Uptake
8%
Treating children
8%
Author Names
8%
WHO Grade IV
8%
Recent Update
8%
Oncologists
8%
WHO Classification of CNS Tumors
8%
WHO 2016
8%
Microvascular Pattern
8%
End-of-life Care
8%
Multi-regional
8%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
8%
Standardized Uptake Value
8%
Effective Compounds
8%
Drug Imaging
8%
Macromolecular Drugs
8%
Phase II Study
8%
Irinotecan
8%
Morphological Heterogeneity
8%
Epigenetic Heterogeneity
8%
Radiological Criteria
8%
Clinical Criteria
8%
Survival Prediction Model
8%
CNS Tumors
8%
Molecular Diagnostics
8%
Tumor Drugs
8%
Diffuse Midline Glioma
8%
PubMed
8%
Blood-brain Barrier
8%
Sirtuin 1 (SIRT1)
8%
Atypical Teratoid Rhabdoid Tumor (AT/RT)
8%
Gemcitabine
8%
Median Overall Survival
8%
Medicine and Dentistry
Pontine Glioma
55%
Ganglioglioma
17%
Neoplasm
15%
Diagnosis
13%
Pediatrics
8%
Central Nervous System Tumor
8%
Positron Emission Tomography
8%
Tumor Classification
8%
Neuropathologist
8%
Pediatric Neurology
8%
Oncologist
8%
Fluorodeoxyglucose F 18
8%
Standardized Uptake Value
8%
Survival Prediction
8%
Morphology
8%
Pons
8%
Sirtuin 1
8%
Gemcitabine
8%
Atypical Teratoid Rhabdoid Tumor
8%
Protein P53
8%
Polyethylene Terephthalate
8%
Clinical Trial
8%
Biopsy Technique
8%
Overall Survival
7%
Pediatric Brain Tumor
6%
Disease
5%
